Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.

“As we position Myriad for its next phase of growth and value creation, the Board and Mark have mutually agreed that now is the right time for a leadership transition,” said John T. Henderson, M.D., Chairman of the Board of Directors. “We are pleased to have a leader with Bryan’s experience to step into the additional role of Interim CEO and provide continuity as we execute on our search for a permanent CEO. Myriad has a significant opportunity to innovate around its business and position itself for sustainable, profitable growth. We are committed to taking the necessary steps to enhance our performance and are confident in the strength of our product pipeline to deliver on our value creation objectives. The Board is focused on identifying the right leader to guide the Company forward as we continue to execute on our critical success factors and position Myriad for meaningful improvement in profitability. We are confident in Bryan’s ability to drive the Company forward and will continue to support him and the entire executive team while we work to identify a permanent CEO.”

Dr. Henderson continued, “On behalf of the entire Board of Directors, I want to thank Mark for his leadership and contributions to Myriad over his more than 17-year tenure with the Company. We have had numerous scientific and medical advances during this time that have contributed significantly to the health and transformation of patients’ lives around the world. We wish him the best in his future endeavors.”

“I have been fortunate to be a part of the Myriad community for more than 17 years and I am proud of our team and what we have accomplished together, driven by our passion of supporting patients and their families around the world,” said Mr. Capone. “I am confident in the future prospects for the business and the ability of Myriad to continue its position as a world leader in personalized medicine.”

Mr. Riggsbee said, “I am committed to driving the business forward and ensuring a smooth leadership transition. We have a highly talented team of employees at Myriad and a strong foundation built upon pioneering science directed toward patient care. I intend to work closely with the Board, the rest of the executive team, and our dedicated employees as we continue to execute on our strategy to drive sustained profitable growth.”

Fiscal Second-Quarter 2020 Financial Results
In a separate release today, the Company disclosed its financial results for its fiscal second-quarter 2020 ended December 31, 2019. The Company will host a conference call with investors and analysts today at 4:30 p.m. ET to review its financial results.

About Bryan Riggsbee
Bryan Riggsbee joined Myriad in October 2014. He previously served for 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. in Accounting from North Carolina State University, a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.